Zoledronic acid in patients with stage IIIA/B NSCLC: Results of a randomized, phase III study

G. V. Scagliotti, P. Kosmidis, F. De Marinis, A. J M Schreurs, I. Albert, W. Engel-Riedel, D. Schallier, S. Barbera, H. P. Kuo, V. Sallo, J. R. Perez, C. Manegold

Research output: Contribution to journalArticle

Abstract

Background: Bone metastases are common in patients with advanced non-small-cell lung cancer (NSCLC) and can have devastating consequences. Preventing or delaying bone metastases may improve outcomes. Patients and methods: This study evaluated whether zoledronic acid (ZOL) delayed disease progression or recurrence in patients with controlled stage IIIA/B NSCLC after first-line therapy. Patients received vitamin D and calcium supplementation and were randomized to i.v. ZOL (every 3-4 weeks) or no treatment (control). The primary end point was progression-free survival (PFS). Results: No significant intergroup differences were observed in PFS or overall survival (OS). Median PFS was 9.0 months with ZOL versus 11.3 months for control. Fifteen ZOL-treated (6.6%) and 19 control patients (9.0%) developed bone metastases. Estimated 1-year OS was 81.8% for each group. ZOL safety profile was consistent with previous clinical data, but with higher discontinuations versus control. Fifteen ZOL-treated (6.6%) and five control patients (2.3%) had renal adverse events. Two cases of osteonecrosis of the jaw were reported. Conclusions: ZOL did not significantly affect PFS or OS in stage IIIA/B NSCLC patients with controlled disease, with a trend toward worsening PFS in the longer-term follow-up. Few patients experienced bone metastases, possibly limiting the potential ZOL impact on disease course.

Original languageEnglish
Article numbermds128
Pages (from-to)2082-2087
Number of pages6
JournalAnnals of Oncology
Volume23
Issue number8
DOIs
Publication statusPublished - Aug 2012

Keywords

  • Adjuvant treatment
  • Non-small-cell lung cancer
  • Survival
  • Zoledronic acid

ASJC Scopus subject areas

  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'Zoledronic acid in patients with stage IIIA/B NSCLC: Results of a randomized, phase III study'. Together they form a unique fingerprint.

  • Cite this

    Scagliotti, G. V., Kosmidis, P., De Marinis, F., Schreurs, A. J. M., Albert, I., Engel-Riedel, W., Schallier, D., Barbera, S., Kuo, H. P., Sallo, V., Perez, J. R., & Manegold, C. (2012). Zoledronic acid in patients with stage IIIA/B NSCLC: Results of a randomized, phase III study. Annals of Oncology, 23(8), 2082-2087. [mds128]. https://doi.org/10.1093/annonc/mds128